Effect of Tacrolimus in treatment of Recurrent Implantation Failure

Phase 3

Recruiting

• Conditions: Recurrent Implantation Failure.

• Registration Number: IRCT20240429061583N1
• Lead Sponsor: Iranian academic center for education culture and research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 27 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 162

Inclusion Criteria

Unexplained RIF
History of Three or more Failed Embryo Transfers

Exclusion Criteria

Patients who Used Immunosuppressive Drugs
Chronic Endometritis
Uterine Anomaly
Active Viral Diseases, Tuberculosis, Invasive Fungal Infections and Bacterial Infections
Patients with High Blood Pressure, Renal Failure, liver Disorder, Heart Failure, Ischemic Heart Disease , Arrhythmia, Untreated Endocrine Disorder
Immunocompromised Patients
Patients with Malignant Tumors
Patients with a history of Organ Transplantation
Patients with a history of Tacrolimus Allergy
Patients with a history of Blood Disorders, Coagulopathy
Antiphospholipid Syndrome and Collagen Vascular Disease
Patients receiving Potassium-Sparing Diuretics
Patients who received Live Vaccine 2 months before admission

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Chemical pregnancy Rate. Timepoint: Day 14 and 16 after embryo transfer. Method of measurement: level of serum ßHCG.;Clinical Pregnancy Rate. Timepoint: 4 to 5 Weeks after Embryo Transfer. Method of measurement: ultrasound and Observe at least one Gestational Sac.

Secondary Outcome Measures

Name	Time	Method
Ongoing Pregnancy Rate. Timepoint: 12 Weeks after Embryo Transfer. Method of measurement: Normal Pregnancy with Fetal Heartbeat in ultrasound.;Abortion Rate. Timepoint: 12 Weeks after Embryo Transfer. Method of measurement: Excretion of Pregnancy Products or Failure to see Fetal Heart in Ultrasound at the end of 12 Weeks.